0000000000172625

AUTHOR

Peggy Dartigues

showing 2 related works from this author

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study

2019

International audience; Background: Increased-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPescalated) improves progression-free survival in patients with advanced Hodgkin lymphoma compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), but is associated with increased risks of haematological toxicity, secondary myelodysplasia or leukaemia, and infertility. We investigated whether PET monitoring during treatment could allow dose de-escalation by switching regimen (BEACOPPescalated to ABVD) in early responders without loss of disease control compared with standard treatment without PET monitoring.Methods: AHL201…

AdultMalemedicine.medical_specialtyVincristineDacarbazine[SDV]Life Sciences [q-bio]Salvage therapy[SDV.CAN]Life Sciences [q-bio]/CancerProcarbazineGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicinehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansComputingMilieux_MISCELLANEOUSNeoplasm Stagingbusiness.industryStandard treatmentmedicine.diseaseHodgkin Disease3. Good healthVinblastineDrug Therapy Computer-Assisted[SDV] Life Sciences [q-bio]OncologyABVD030220 oncology & carcinogenesisPositron-Emission TomographyFemalebusinessFebrile neutropenia030215 immunologymedicine.drug
researchProduct

Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Pr…

2021

PURPOSE A dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab (DA-EPOCH-R) regimen has been shown to deliver excellent survival for adults with primary mediastinal large B-cell lymphoma (PMLBL) without the use of radiotherapy. No international prospective evaluation of this regimen has previously been reported in children and adolescents. PATIENTS AND METHODS We conducted an international single-arm phase II trial involving patients younger than age 18 years with PMLBL who were to receive six courses of DA-EPOCH-R. The primary end point was event-free survival (EFS). Overall survival and toxicity were also assessed. This trial was regist…

OncologyCancer Researchmedicine.medical_specialtyVincristineCyclophosphamidebusiness.industryORIGINAL REPORTSmedicine.diseaseRegimenOncologyPrednisoneInternal medicinemedicineRituximabDoxorubicinPrimary mediastinal B-cell lymphomabusinessEtoposidemedicine.drugJournal of Clinical Oncology
researchProduct